Results 61 to 70 of about 306 (142)
Mechanistic Modeling of cfDNA Fragmentome Dynamics Predicts Progression to Immunotherapy
BackgroundPlasma cell-free DNA (cfDNA) shows promise as predictive cancer biomarker, but mechanisms governing cfDNA production/fragmentation/elimination dynamics, and their relationships with tumor burden and disease progression, remain poorly understood.
Boutonnet, Audrey +9 more
core +3 more sources
Leveraging cfDNA fragmentomic features for the early detection of colorectal cancer
Background Early detection of colorectal cancer (CRC) is crucial for improving patient outcomes. Cell-free DNA (cfDNA) analysis has emerged as a promising non-invasive approach for cancer detection. This study aims to develop a machine learning algorithm leveraging cfDNA fragmentomic features to accurately ...
Shan, Lina +11 more
openaire +2 more sources
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels
Abstract Fragmentomics based analysis of cell-free DNA (cfDNA) has recently emerged as a method to infer epigenetic and transcriptional data. Many of these reports analyze whole genome sequencing (WGS) which is not readily available clinically. Targeted exon panels are used for clinical cfDNA variant calling.
Kyle T. Helzer +26 more
openaire +3 more sources
Computational modeling approaches for circulating cellfree DNA in oncology
International audienceMany cancer patients undergoing immune-checkpoint inhibition (ICI) experience early progression (EP), defined as progression at the first imaging evaluation.
Nguyen Phuong, Linh
core +3 more sources
International audienceBackground: Immune-checkpoint inhibition (ICI) has significantly advanced cancer treatment, but many patients experience early progression (EP).
Boutonnet, Audrey +9 more
core +1 more source
Innovations in Early Lung Cancer Detection: Tracing the Evolution and Advancements in Screening
Lung cancer mortality rates, particularly non-small cell lung cancer (NSCLC), continue to present a significant global health challenge, and the adoption of lung cancer screening remains limited, often influenced by inequities in access to healthcare ...
Demetria Tennefoss +7 more
core +1 more source

